Literature DB >> 20425609

Neurotoxicity of cancer treatment.

Marc C Chamberlain1.   

Abstract

Cancer therapy--including brain-directed surgery, brain or spine irradiation, or chemotherapy--may affect the nervous system in a deleterious manner, affecting either the central or peripheral nervous systems. The causation of encephalopathy (eg, radiation, chemotherapy) is most relevant for the differential diagnosis of central nervous system (CNS) disorders, as defining a specific cause determines further treatment and outcome. Peripheral nervous system disorders (ie, steroid myopathy, spindle poison, or platinum neuropathy) are predominantly treatment related and respond best to discontinuation of the neurotoxic agent.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20425609     DOI: 10.1007/s11912-009-0072-9

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.945


  46 in total

1.  Health-related quality of life in patients with glioblastoma: a randomised controlled trial.

Authors:  Martin J B Taphoorn; Roger Stupp; Corneel Coens; David Osoba; Rolf Kortmann; Martin J van den Bent; Warren Mason; René O Mirimanoff; Brigitta G Baumert; Elizabeth Eisenhauer; Peter Forsyth; Andrew Bottomley
Journal:  Lancet Oncol       Date:  2005-12       Impact factor: 41.316

2.  Limitations of stereotactic biopsy in the initial management of gliomas.

Authors:  R J Jackson; G N Fuller; D Abi-Said; F F Lang; Z L Gokaslan; W M Shi; D M Wildrick; R Sawaya
Journal:  Neuro Oncol       Date:  2001-07       Impact factor: 12.300

Review 3.  The radioresponse of the central nervous system: a dynamic process.

Authors:  P J Tofilon; J R Fike
Journal:  Radiat Res       Date:  2000-04       Impact factor: 2.841

4.  Treatment of radiation-induced nervous system injury with heparin and warfarin.

Authors:  M J Glantz; P C Burger; A H Friedman; R A Radtke; E W Massey; S C Schold
Journal:  Neurology       Date:  1994-11       Impact factor: 9.910

Review 5.  Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.

Authors:  Dieta Brandsma; Lukas Stalpers; Walter Taal; Peter Sminia; Martin J van den Bent
Journal:  Lancet Oncol       Date:  2008-05       Impact factor: 41.316

Review 6.  Nervous system infections in patients with cancer.

Authors:  Amy A Pruitt
Journal:  Neurol Clin       Date:  2003-02       Impact factor: 3.806

7.  Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project.

Authors:  Susan M Chang; Ian F Parney; Michael McDermott; Fred G Barker; Meic H Schmidt; Wei Huang; Edward R Laws; Kevin O Lillehei; Mark Bernstein; Henry Brem; Andrew E Sloan; Mitchel Berger
Journal:  J Neurosurg       Date:  2003-06       Impact factor: 5.115

8.  Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.

Authors:  Christina A Meyers; Jennifer A Smith; Andrea Bezjak; Minesh P Mehta; James Liebmann; Tim Illidge; Ian Kunkler; Jean-Michel Caudrelier; Peter D Eisenberg; Jacobus Meerwaldt; Ross Siemers; Christian Carrie; Laurie E Gaspar; Walter Curran; See-Chun Phan; Richard A Miller; Markus F Renschler
Journal:  J Clin Oncol       Date:  2004-01-01       Impact factor: 44.544

9.  Depression in patients with high-grade glioma: results of the Glioma Outcomes Project.

Authors:  N Scott Litofsky; Elana Farace; Frederick Anderson; Christina A Meyers; Wei Huang; Edward R Laws
Journal:  Neurosurgery       Date:  2004-02       Impact factor: 4.654

Review 10.  Radiation induced CNS toxicity--molecular and cellular mechanisms.

Authors:  C Belka; W Budach; R D Kortmann; M Bamberg
Journal:  Br J Cancer       Date:  2001-11-02       Impact factor: 7.640

View more
  8 in total

Review 1.  Central nervous system injury and neurobiobehavioral function in children with brain tumors: a review of the literature.

Authors:  Mary Baron Nelson; Peggy Compton; Sunita K Patel; Eufemia Jacob; Ronald Harper
Journal:  Cancer Nurs       Date:  2013 Mar-Apr       Impact factor: 2.592

Review 2.  Chemotherapy-Related Neurotoxicity.

Authors:  Sophie Taillibert; Emilie Le Rhun; Marc C Chamberlain
Journal:  Curr Neurol Neurosci Rep       Date:  2016-09       Impact factor: 5.081

Review 3.  Postradiation lower motor neuron syndrome: case series and literature review.

Authors:  A Abraham; V E Drory
Journal:  J Neurol       Date:  2013-03-05       Impact factor: 4.849

Review 4.  Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned.

Authors:  Harold L Atkins; Mark S Freedman
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

5.  The α9α10 Nicotinic Acetylcholine Receptor Antagonist αO-Conotoxin GeXIVA[1,2] Alleviates and Reverses Chemotherapy-Induced Neuropathic Pain.

Authors:  Huanbai Wang; Xiaodan Li; Dongting Zhangsun; Gang Yu; Ruibin Su; Sulan Luo
Journal:  Mar Drugs       Date:  2019-05-05       Impact factor: 5.118

6.  A Chemo-Genomic Approach Identifies Diverse Epigenetic Therapeutic Vulnerabilities in MYCN-Amplified Neuroblastoma.

Authors:  Aleksandar Krstic; Anja Konietzny; Melinda Halasz; Peter Cain; Udo Oppermann; Walter Kolch; David J Duffy
Journal:  Front Cell Dev Biol       Date:  2021-04-21

Review 7.  Neurotoxicity associated with cancer therapy.

Authors:  Eva Lu Lee; Laurel Westcarth
Journal:  J Adv Pract Oncol       Date:  2012-01

8.  Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma.

Authors:  Ni Fan; Lu Zhang; Xiaoping Xu; Bobin Chen; Chen Zhu; Pei Li; Zi Chen; Tianling Ding; Yan Ma; Yan Yuan; Zhiguang Lin
Journal:  Oncotarget       Date:  2017-03-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.